NGL Fine-Chem Profit Soars 128% to ₹48 Cr on Strong 36% Revenue Growth

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
NGL Fine-Chem Profit Soars 128% to ₹48 Cr on Strong 36% Revenue Growth
Overview

NGL Fine-Chem announced a strong fiscal year 2026, with profit after tax jumping 128% to ₹48.13 crore and revenue increasing 36% to ₹500.95 crore. The growth was fueled by higher sales volumes and contributions from its Phase I capital expenditure, though geopolitical factors increased costs.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

NGL Fine-Chem Reports Strong FY26 Financial Results

NGL Fine-Chem Limited announced its financial results for the fiscal year 2026, revealing a substantial 36.03% year-on-year increase in revenue from operations to ₹500.95 crore. The company's Profit After Tax (PAT) for the year surged by 127.83% to ₹48.13 crore, while EBITDA grew by 114.62% to ₹72.69 crore.

Key Financial Highlights

The strong financial performance was driven by increased sales volumes across products and markets, supported by the ongoing contribution from Phase I of the company's capital expenditure program. Management is emphasizing disciplined execution to ensure sustained growth.

Growth Drivers and Challenges

This robust performance signals a positive turnaround for NGL Fine-Chem, highlighting effective operational management and rising market demand. The company's successful leverage of expanded capacity from Phase I capex is a primary driver. However, geopolitical volatility has led to increased freight and raw material costs, impacting margins, particularly on fixed-price contracts.

Operational Context

The company's strong fiscal year results follow three consecutive quarters of solid volume growth, demonstrating a clear recovery path. The partial success in passing price increases to customers is expected to aid in restoring margins that were pressured by rising input costs.

Future Outlook and Risks

Execution of capital expenditure plans, especially Phase II, remains a focus. Delays in commissioning Phase II, due to gas and labor availability, could affect the growth timeline. Geopolitical factors continue to pose a risk, potentially pressuring future margins if cost increases cannot be fully passed on to customers.

Upcoming Milestones

Investors will be tracking the commissioning of Phase II capex, now expected in early Q2FY27, and the planned commencement of commercial production in H2FY27. Monitoring the impact of price adjustments on margin recovery will also be key.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.